The 6th Annual Symposium on Dec. 9 and 10 will feature renowned experts to explore cutting-edge concepts in health research and innovation.
Newly-generated cells may lead to a deeper understanding of bile duct disease and be a powerful tool for finding new treatments.
Entrepreneur-in-residence to work on bridging the gap between foundational research funded by Medicine by Design and the creation of products or ventures that will impact human health.
The program’s second year includes new partnerships, enhanced educational opportunities and more research funding.
Scientists at the University of Toronto have discovered a novel way to test self-repair of skeletal muscle, a method with the potential to accelerate treatments for diseases like muscular dystrophy.
Regen Med in the Clinic, a new partnership between the Ajmera Transplant Centre and Medicine by Design, aims to create linkages between clinicians and scientists & engineers.
Convergence is the key to advancing regenerative medicine and paving the way for novel approaches to treating disease and even preventing it before it starts. This post is just one of many covering the topic of aging as part of Signal’s sixth annual blog carnival.
Funding gives cutting-edge regenerative medicine concepts impacting heart disease, lung transplantation, degenerative brain disease and end-stage liver disease a pathway to clinical translation.
Meeting from August 25 to 27 will focus on development and pediatric communities
Computational biology study found two fundamental mechanisms involved in the cell play important roles and may help better control cells used in regenerative medicine applications
Three investigators join a cohort of 15 faculty members who have been supported by Medicine by Design’s New Investigators program.
What if manufacturing proteins was a simple as brewing a cup of coffee?
Research team looks to blood for answers on why aging can cause inflammation and disease
Thanks to this team’s effective storytelling, sound science and clear pathway to translation, HDAX was chosen by the judges to receive research funding.
The doctoral exchange is part of a larger partnership called the Leukemia Consortium, which seeks to generate a comprehensive data set pertaining to human blood stem cells and the leukemia that originates from them.
